+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Syncytial Virus Therapeutic Drugs Market by Product Type, Route Of Administration, Patient Type, End User, Distribution Channel - Global Forecast to 2030- Product Image
Respiratory Syncytial Virus Therapeutic Drugs Market by Product Type, Route Of Administration, Patient Type, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Respiratory Syncytial Virus Therapeutic Drugs Market by Product Type, Route Of Administration, Patient Type, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081500
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

RSV Therapeutics: Charting the Evolution of Disease Management

Respiratory Syncytial Virus (RSV) poses a significant clinical challenge across diverse patient populations, demanding innovative therapeutic interventions that can effectively mitigate severe outcomes. Over the past decade, progress in monoclonal antibodies, small molecule therapies, and vaccines has transformed RSV management from largely supportive care to proactive disease prevention and targeted treatment. An in-depth exploration of these therapeutic classes reveals how scientific breakthroughs, regulatory approvals, and shifting care pathways converge to address unmet medical needs and improve patient quality of life.

This executive summary delves into the current landscape of RSV therapeutics, highlighting key developments that drive industry momentum. By examining the mechanisms of action, clinical trial milestones, and regulatory milestones of leading candidates, readers will gain a comprehensive understanding of the factors shaping market dynamics. Moreover, this overview sets the stage for strategic decision-making by illuminating competitive differentiators, adoption barriers, and emerging opportunities. The subsequent sections will unpack paradigm shifts in treatment approaches, tariff-related headwinds, segmentation nuances, regional trends, competitive strategies, and actionable recommendations for stakeholders aiming to capitalize on this evolving market.

From Supportive Care to Precision Interventions: Paradigm Shifts in RSV Management

The RSV therapeutic landscape has undergone a profound transformation, moving from reactive supportive care toward precision interventions that disrupt viral propagation. Monoclonal antibodies have shifted from infancy to a frontline prophylactic approach, extending protection windows for vulnerable neonates and high-risk adults. Concurrently, fusion and polymerase inhibitors advance through late-stage trials, promising oral treatment options that counteract symptomatic progression and reduce hospitalization rates.

Vaccines represent another seismic shift, with live attenuated, messenger RNA, and recombinant platforms unlocking durable immunity profiles across age groups. Early pediatric studies demonstrate enhanced immunogenicity, while adult and geriatric cohorts benefit from dose-sparing regimens that bolster cellular memory responses. This multipronged vaccine strategy redefines the prevention paradigm, enabling public health initiatives to integrate RSV immunization alongside established influenza and pneumococcal programs.

Collectively, these innovations illustrate how collaborative efforts between biotechnology firms, academic consortia, and regulatory bodies catalyze rapid iteration of clinical protocols and adaptive trial designs. As real-world evidence accumulates, healthcare systems will increasingly adopt these transformative therapies to mitigate seasonal RSV surges and reduce the long-term burden on hospital infrastructure.

Navigating 2025 Tariffs: Supply Chain Resilience and Cost Management for RSV Drugs

The imposition of updated United States tariffs in 2025 has introduced a new dimension of complexity for RSV therapeutic developers and distributors. Import duties on active pharmaceutical ingredients and specialized biologics manufacturing equipment have led to increased production overheads, which, in turn, influence pricing negotiations and reimbursement discussions. Despite these headwinds, manufacturers have employed strategic sourcing diversification and nearshoring to sustain supply chains and protect margin integrity.

Tariff-induced cost pressures have prompted outsourcing partnerships and technology transfer agreements, enabling manufacturers to leverage domestic contract development and manufacturing organizations. This localized capacity expansion not only mitigates duty exposure but also enhances regulatory agility, particularly for fast-track designations and emergency use authorizations. Payers and healthcare providers, meanwhile, are exploring value-based contracting arrangements to align price points with clinical outcomes, thus absorbing some of the tariff-related cost shifts through risk-sharing models.

Ultimately, the 2025 tariff scenario underscores the importance of integrated cross-functional planning, where procurement teams, regulatory affairs specialists, and commercial strategists collaborate to optimize supply chain resilience and maintain patient access. As stakeholders adapt to this evolving trade environment, the lessons learned will inform broader strategies for global market entry and cost containment.

Unpacking Market Segments: Therapy Classes, Patient Profiles, and Care Pathways

Insightful analysis of product type segmentation reveals that monoclonal antibodies dominate current RSV prophylaxis efforts, led by long-acting candidates such as Nirsevimab alongside established options like Palivizumab, while small molecule therapies focused on fusion and polymerase inhibition gain footholds as next-generation treatment modalities. Vaccine development spans live attenuated, messenger RNA, and recombinant technologies, each offering unique immunogenic profiles and logistical considerations for cold chain deployment.

Route of administration segmentation highlights that intramuscular injections remain the primary delivery method for antibodies and vaccines, whereas oral formulations of fusion and polymerase inhibitors introduce patient-centric convenience. Intravenous dosing, reserved for acute hospital settings, complements subcutaneous self-administration options that empower home healthcare models.

Patient type analysis differentiates adult, geriatric, and pediatric cohorts, with middle-aged and younger adults targeted for emerging antiviral regimens, and specialized infant, neonate, and toddler protocols addressing the highest risk groups. Geriatric populations, particularly those aged 65 and above, benefit from tailored immunization schedules that account for immunosenescence and comorbidity profiles.

End user segmentation underscores that hospitals, encompassing both private and public institutions, remain critical adoption centers for acute interventions, while outpatient and specialty clinics expand preventive outreach. Home healthcare models, featuring caregiver-administered or self-administered dosing, complement distribution channel frameworks that include hospital, online, and retail pharmacies to ensure broad product accessibility.

Regional Dynamics: Adoption Patterns and Market Access Across Key Territories

Regional dynamics in the Americas center on robust public health campaigns and established immunization infrastructures that accelerate the adoption of prophylactic agents, while healthcare payers wrestle with balancing upfront costs against long-term hospitalization savings. The United States market remains a bellwether for innovative pricing models and regulatory fast-tracking, whereas Latin American countries navigate access programs and tiered pricing agreements to bridge affordability gaps.

In Europe, Middle East & Africa, diverse regulatory landscapes and variable healthcare funding mechanisms create both challenges and opportunities. Western European nations prioritize high-efficacy vaccines and advanced biologics with integrated pharmacovigilance systems, while emerging markets in the Middle East and Africa pursue strategic partnerships to build local manufacturing capacity and adapt cold chain solutions to resource-constraint settings.

Asia-Pacific encompasses a wide spectrum of market maturity, from leading economies with domestic vaccine production and clinical trial hubs to developing regions that rely on imported therapies. National immunization committees in this region are integrating RSV vaccines into pediatric schedules, and private-public collaborations are enhancing distribution networks to reach rural communities. As a result, market entry strategies must account for heterogeneous regulatory requirements, pricing benchmarks, and healthcare delivery models across these territories.

Competitive Forces Shaping Innovation and Partnership Strategies

The competitive landscape in RSV therapeutics is shaped by a blend of established pharmaceutical powerhouses and agile biotechnology innovators. Leading antibody developers have secured priority review designations and leveraged real-world evidence to fortify reimbursement dossiers, while emerging small molecule specialists employ structure-guided design to optimize oral bioavailability and viral target binding.

Vaccine contenders are forging collaborations with contract manufacturing organizations to scale mRNA and recombinant platforms, and clinical partnerships with academic institutions are accelerating phase III and IV study enrollment. Companies adept at integrating digital health technologies into patient monitoring and adherence programs gain a distinct advantage in demonstrating real-world effectiveness and differentiating their value proposition.

Additionally, key players are pursuing geographic expansion through in-licensing agreements and co-development deals that extend their global footprint. Cross-sector alliances, including those with diagnostics providers, aim to establish comprehensive RSV management ecosystems that encompass early detection, targeted treatment, and longitudinal health data analytics. Such synergies are poised to reshape the competitive hierarchy and drive integrated care solutions.

Strategies to Secure Value-Based Access and Fortify Supply Chain Resilience

Industry leaders should prioritize forging integrated value-based agreements with payers and providers to align therapeutic pricing with demonstrated patient outcomes. By benchmarking clinical efficacy against historical hospitalization and complication rates, companies can structure risk-sharing contracts that incentivize broad access while safeguarding revenue stability.

Investing in regional manufacturing hubs and contract development partnerships will mitigate trade-related cost pressures and ensure rapid scale-up capabilities. A proactive supply chain resilience plan-encompassing dual sourcing, inventory buffers, and regulatory alignment-will enable uninterrupted market supply and reinforce stakeholder confidence in product availability.

Moreover, cross-functional collaboration between clinical, commercial, and digital health teams will be critical to designing seamless patient journeys. Embedding telehealth support, adherence tracking applications, and real-world evidence platforms can enhance therapeutic uptake and demonstrate longitudinal benefits, thereby strengthening value propositions during pricing negotiations and formulary inclusion processes.

Robust Research Framework Leveraging Multi-Source Data and Expert Validation

This analysis integrates primary interviews with key opinion leaders in immunology, virology, and health economics, supplemented by surveys of hospital pharmacy directors and outpatient clinic administrators to capture real-world adoption barriers and opportunities. Secondary research encompasses regulatory filings, clinical trial registries, peer-reviewed publications, and proprietary databases tracking therapeutic approvals and pricing benchmarks.

Data synthesis followed a multilayered validation protocol, triangulating findings across diverse sources to ensure accuracy and relevance. Quantitative insights were contextualized through qualitative expert input, enabling nuanced interpretations of emerging clinical trial outcomes, tariff impacts, and segmentation trends. Geographic and company-specific analyses employed econometric modeling and scenario planning to account for variations in healthcare funding, regulatory timelines, and competitive landscapes.

Ongoing updates to this methodology incorporate feedback loops with advisory board members and real-time monitoring of policy changes, ensuring that the report remains a reliable strategic tool for stakeholders navigating the complex RSV therapeutics environment.

Synthesizing Insights to Drive Strategic Impact in RSV Therapeutics

Respiratory Syncytial Virus therapeutics represent a rapidly evolving frontier in respiratory medicine, characterized by innovative monoclonal antibodies, advanced small molecule inhibitors, and diverse vaccine platforms. Transformative shifts in clinical paradigms, coupled with emerging tariff challenges, segmentation nuances, and regional adoption dynamics, underscore the multifaceted considerations that industry stakeholders must navigate.

A comprehensive view of competitive strategies reveals that partnerships, value-based contracting, and digital health integration are critical levers for driving market uptake and differentiating offerings. By synthesizing empirical evidence from clinical trials, real-world settings, and expert insights, strategic decision-makers can craft initiatives that balance cost, access, and patient outcomes.

As the RSV therapeutic market continues to mature, aligning supply chain resilience, pricing models, and patient-centred care pathways will be essential to unlocking the full potential of these groundbreaking interventions and improving respiratory health outcomes across global populations.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Monoclonal Antibody
      • Nirsevimab
      • Palivizumab
    • Small Molecule Therapy
      • Fusion Inhibitor
      • Polymerase Inhibitor
    • Vaccine
      • Live Attenuated Vaccine
      • Messenger Rna Vaccine
      • Recombinant Vaccine
  • Route Of Administration
    • Intramuscular
    • Intravenous
    • Oral
    • Subcutaneous
  • Patient Type
    • Adult
      • Middle Aged
      • Older Adult
      • Younger Adult
    • Geriatric
    • Pediatric
      • Infant
      • Neonate
      • Toddler
  • End User
    • Clinic
      • Outpatient Clinic
      • Specialty Clinic
    • Home Healthcare
      • Caregiver Administration
      • Self Administration
    • Hospital
      • Private Hospital
      • Public Hospital
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AstraZeneca PLC
  • Sanofi S.A.
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Moderna, Inc.
  • Novavax, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Syncytial Virus Therapeutic Drugs Market, by Drug Type
8.1. Introduction
8.2. Antiviral Agents
8.2.1. Palivizumab
8.2.2. Ribavirin
8.3. Immunotherapy
8.3.1. Cell-Based Therapies
8.3.2. Monoclonal Antibodies
9. Respiratory Syncytial Virus Therapeutic Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.2.1. Inhalers
9.2.2. Nebulizers
9.3. Injection
9.3.1. Intramuscular
9.3.2. Intravenous
9.4. Oral
9.4.1. Capsules
9.4.2. Tablets
10. Respiratory Syncytial Virus Therapeutic Drugs Market, by Drug Approval Status
10.1. Introduction
10.2. Approved Drugs
10.2.1. EMA Approved
10.2.2. FDA Approved
10.3. Pipeline Drugs
10.3.1. Phase I
10.3.2. Phase II
10.3.3. Phase III
11. Respiratory Syncytial Virus Therapeutic Drugs Market, by Patient Demographics
11.1. Introduction
11.2. Adult Patients
11.2.1. Aged 18-64
11.2.2. Elderly Aged 65+
11.3. Pediatric Patients
11.3.1. Infants
11.3.2. Toddlers
12. Respiratory Syncytial Virus Therapeutic Drugs Market, by Disease Severity
12.1. Introduction
12.2. Mild Cases
12.2.1. Outpatient Treatment
12.3. Severe Cases
12.3.1. Hospitalization Required
12.3.2. ICU Admission
13. Respiratory Syncytial Virus Therapeutic Drugs Market, by End-User
13.1. Introduction
13.2. Clinics
13.2.1. General Clinics
13.2.2. Specialty Clinics
13.3. Hospitals
13.3.1. Private Hospitals
13.3.2. Public Hospitals
14. Respiratory Syncytial Virus Therapeutic Drugs Market, by Distribution Channel
14.1. Introduction
14.2. Hospital Pharmacies
14.2.1. In-Store
14.2.2. Mail Order
14.3. Online Pharmacies
14.3.1. E-Pharmacy Websites
14.4. Retail Pharmacies
14.4.1. Chain Pharmacies
14.4.2. Independent Pharmacies
15. Respiratory Syncytial Virus Therapeutic Drugs Market, by Mechanism Of Action
15.1. Introduction
15.2. Fusion Inhibitors
15.3. RSV Protease Inhibitors
15.4. Small Molecule Inhibitors
15.4.1. Nucleoside Analogues
15.4.2. RNase Inhibitors
16. Americas Respiratory Syncytial Virus Therapeutic Drugs Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Respiratory Syncytial Virus Therapeutic Drugs Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Respiratory Syncytial Virus Therapeutic Drugs Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Ablynx - A Sanofi Company
19.3.2. AstraZeneca
19.3.3. Boehringer Ingelheim
19.3.4. GlaxoSmithKline (GSK)
19.3.5. GSK
19.3.6. Johnson & Johnson
19.3.7. Merck & Co., Inc.
19.3.8. Moderna, Inc.
19.3.9. Novartis AG
19.3.10. Pfizer, Inc.
19.3.11. Regeneron Pharmaceuticals, Inc.
19.3.12. Roche Holding AG
19.3.13. Sanofi S.A.
19.3.14. Vir Biotechnology, Inc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 22. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PALIVIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RIBAVIRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CELL-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY APPROVED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY EMA APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY FDA APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY APPROVED DRUGS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PIPELINE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PIPELINE DRUGS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY AGED 18-64, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ELDERLY AGED 65+, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MILD CASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY OUTPATIENT TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MILD CASES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SEVERE CASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALIZATION REQUIRED, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ICU ADMISSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SEVERE CASES, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IN-STORE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MAIL ORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY E-PHARMACY WEBSITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RSV PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RNASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY APPROVED DRUGS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PIPELINE DRUGS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MILD CASES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SEVERE CASES, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY APPROVED DRUGS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PIPELINE DRUGS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MILD CASES, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SEVERE CASES, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY APPROVED DRUGS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PIPELINE DRUGS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MILD CASES, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SEVERE CASES, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, 2018-2030 (USD MILLION)
TABLE 161. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 162. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 164. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 165. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 166. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 167. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY APPROVED DRUGS, 2018-2030 (USD MILLION)
TABLE 168. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PIPELINE DRUGS, 2018-2030 (USD MILLION)
TABLE 169. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 170. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 171. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 172. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 173. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MILD CASES, 2018-2030 (USD MILLION)
TABLE 174. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SEVERE CASES, 2018-2030 (USD MILLION)
TABLE 175. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 177. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 181. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 182. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. CANADA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, 2018-2030 (USD MILLION)
TABLE 186. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 187. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 189. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 190. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 191. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 192. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY APPROVED DRUGS, 2018-2030 (USD MILLION)
TABLE 193. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PIPELINE DRUGS, 2018-2030 (USD MILLION)
TABLE 194. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 195. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 196. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 197. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 198. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MILD CASES, 2018-2030 (USD MILLION)
TABLE 199. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SEVERE CASES, 2018-2030 (USD MILLION)
TABLE 200. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 202. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 203. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 205. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 206. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 207. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. MEXICO RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY APPROVED DRUGS, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PIPELINE DRUGS, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MILD CASES, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SEVERE CASES, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJECTION, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG APPROVAL STATUS, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY APPROVED DRUGS, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PIPELINE DRUGS, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MILD CASES, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SEVERE CASES, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ANTIVIRAL AGENTS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS THERAPEUTIC DRUGS MARKET SIZE, BY INJEC

Companies Mentioned

The companies profiled in this Respiratory Syncytial Virus Therapeutic Drugs market report include:
  • AstraZeneca PLC
  • Sanofi S.A.
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Moderna, Inc.
  • Novavax, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutics Market Report 2025 - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F - Product Image

Respiratory Syncytial Virus (RSV) Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

  • Report
  • 182 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2024 - Product Image

Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 281 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.